Yicura BioMed Closes First Tranche of Series B Led by Gobi Partners
Gobi Partners led the first close of Yicura BioMed's Series B, funding its ICVAX HIV DNA vaccine toward Phase II after a favorable Phase I trial. Amounts undisclosed.
Topic
Gobi Partners
Topic
Gobi Partners
Gobi's Chibo Tang Asks Whether Hong Kong Can Turn Research Into Global Tech
Gobi Partners managing director Chibo Tang poses a pointed question in TNGlobal's HK Special Report: can Hong Kong convert its wo…
Gobi Partners Brings Chinese VC Playbook to Central Asia
Gobi Partners chairman Thomas G. Tao sees DeepTech, smart-city tech and logistics deals in Kazakhstan as the next leg of a five-r…